Salix Pharma up 18% on positive trial results

Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) rose by 18% this morning after the company announced positive clinical trial results from a study of Rifaximin, its potential treatment for irritable bowel syndrome.

The Orlando, Fla.-based pharmaceutical company said at 9:00 am ET that symptoms of patients treated with Rifaximin improved more than in patients treated with a placebo.

By midday the stock is at $6.74, up $1.06 from Friday’s close. Shares have traded as low as $5.34 and as high as $13.33 in the past year.

For detailed price information and news stories on Salix Pharmaceuticals, click SLXP.

For access to the full article, you must be a registered member - it's FREE.

Already a member? Please log in below